AUPH
Aurinia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$16.08
−0.25%Sep 3, 2026, 12:08 UTC
LB Pharmaceuticals Inc. appointed Joseph M. Miller as Chief Financial Officer, effective September 2, 2026, with an annual base salary of $530,000 and a target bonus of 40% of base salary.
Aug 19, 2026, 20:05 UTC
Aurinia Pharmaceuticals settled patent litigation with Teva Pharmaceuticals, resolving the dispute between the two companies.
Aug 6, 2026, 12:00 UTC
Aurinia Pharmaceuticals reported financial results for the three and six months ended June 30, 2026.
Source:Jul 6, 2026, 12:00 UTC
Aurinia Pharmaceuticals initiated the PRESERVE Phase 4 study investigating LUPKYNIS combined with belimumab, obinutuzumab or anifrolumab in lupus nephritis patients.
Source:Jun 4, 2026, 12:33 UTC
Aurinia Pharmaceuticals acquired Kezar Life Sciences.
Source: